Commonwealth Equity Services LLC Has $7.18 Million Stake in Cencora, Inc. (NYSE:COR)

Commonwealth Equity Services LLC trimmed its stake in Cencora, Inc. (NYSE:COR) by 4.2% in the fourth quarter, HoldingsChannel.com reports. The firm owned 31,967 shares of the company’s stock after selling 1,417 shares during the period. Commonwealth Equity Services LLC’s holdings in Cencora were worth $7,182,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. CFO4Life Group LLC increased its holdings in Cencora by 7.2% in the fourth quarter. CFO4Life Group LLC now owns 1,293 shares of the company’s stock valued at $291,000 after purchasing an additional 87 shares during the period. Skandinaviska Enskilda Banken AB publ increased its holdings in Cencora by 122.6% in the fourth quarter. Skandinaviska Enskilda Banken AB publ now owns 342,582 shares of the company’s stock valued at $76,982,000 after purchasing an additional 188,660 shares during the period. Achmea Investment Management B.V. increased its holdings in Cencora by 8.5% in the fourth quarter. Achmea Investment Management B.V. now owns 125,870 shares of the company’s stock valued at $28,281,000 after purchasing an additional 9,857 shares during the period. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Cencora by 236.6% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 10,043 shares of the company’s stock valued at $2,256,000 after purchasing an additional 7,059 shares during the period. Finally, Avantax Advisory Services Inc. grew its holdings in Cencora by 2.1% during the 4th quarter. Avantax Advisory Services Inc. now owns 17,182 shares of the company’s stock worth $3,860,000 after acquiring an additional 351 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Cencora

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of Cencora stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at approximately $5,241,249.24. The trade was a 9.03 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the transaction, the chief executive officer now owns 51,070 shares of the company’s stock, valued at $13,022,850. This trade represents a 8.87 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,970 shares of company stock worth $2,998,670. Insiders own 10.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wells Fargo & Company lifted their price objective on Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Mizuho assumed coverage on Cencora in a research report on Wednesday, December 4th. They issued an “outperform” rating and a $280.00 price objective for the company. StockNews.com raised Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. JPMorgan Chase & Co. lifted their price objective on Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, Evercore ISI lifted their price objective on Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat, Cencora currently has an average rating of “Moderate Buy” and a consensus price target of $280.20.

Cencora Stock Performance

Shares of Cencora stock opened at $267.78 on Friday. Cencora, Inc. has a one year low of $214.77 and a one year high of $267.92. The firm has a market capitalization of $51.93 billion, a price-to-earnings ratio of 38.09, a PEG ratio of 1.31 and a beta of 0.51. The business has a 50-day simple moving average of $250.01 and a 200 day simple moving average of $239.87. The company has a debt-to-equity ratio of 16.40, a current ratio of 0.92 and a quick ratio of 0.54.

Cencora (NYSE:COR) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, beating analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Shareholders of record on Friday, February 14th were paid a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, February 14th. This represents a $2.20 dividend on an annualized basis and a yield of 0.82%. Cencora’s dividend payout ratio (DPR) is currently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.